MedTrace Logo

The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

NCT04447768 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-10-14

No results posted yet for this study

Summary

This study will help researchers collect more information about how effective the combination of venetoclax and obinutuzumab is in treating CLL in people who have not received a previous treatment for their cancer.

Conditions

  • Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG

Obinutuzumab

Cycle 1, Day 1- 100 mg Cycle 1, Day 2 - 900 mg Cycle 1, Day 8 - 1000 mg Cycle 1, Day 15 -1000 mg Cycle 2, Day 1 to Cycle 6, Day 1- 1000 mg

DRUG

Venetoclax

Cycle 1, Day 22 to 28 -20 mg daily Cycle 2, Day 1 to Day 7 -50 mg daily Cycle 2, Day 8 to Day 14- 100 mg daily Cycle 2, Day 15 to Day 21- 200 mg daily Cycle 2, Day 22 to Day 28 - 400 mg daily Cycle 3, Day 1 to end of Cycle 12-24 - 400 mg daily

Sponsors & Collaborators

Principal Investigators

  • Meghan Thompson, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-03
Primary Completion
2026-07-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04447768 on ClinicalTrials.gov